{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:09:31Z","timestamp":1778872171565,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1245\/s10434-026-19260-6","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:37:23Z","timestamp":1772116643000},"page":"4991-5001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3235-2946","authenticated-orcid":false,"given":"Eyal","family":"Mor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Apte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy K.","family":"Broman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina J.","family":"Hieken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell S.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke M.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Ollila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C. J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Gyorki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"23","key":"19260_CR1","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMOA1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322. https:\/\/doi.org\/10.1056\/NEJMOA1613210.","journal-title":"N Engl J Med."},{"issue":"19","key":"19260_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMOA1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMOA1709030.","journal-title":"N Engl J Med."},{"issue":"19","key":"19260_CR3","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMOA1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355. https:\/\/doi.org\/10.1056\/NEJMOA1611299.","journal-title":"N Engl J Med."},{"issue":"19","key":"19260_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMOA1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMOA1802357.","journal-title":"N Engl J Med."},{"key":"19260_CR5","unstructured":"R core team: R: a language and environment for statistical computing. R foundation for statistical computing,\u00a0Vienna, Austria; 2023"},{"issue":"19","key":"19260_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMOA1802357\/SUPPL_FILE\/NEJMOA1802357_DISCLOSURES.PDF","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMOA1802357\/SUPPL_FILE\/NEJMOA1802357_DISCLOSURES.PDF.","journal-title":"N Engl J Med."},{"issue":"19","key":"19260_CR7","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMOA1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u201323. https:\/\/doi.org\/10.1056\/NEJMOA1708539.","journal-title":"N Engl J Med."},{"issue":"30","key":"19260_CR8","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136\/ASSET\/IMAGES\/LARGE\/JCO.23.01136TA2.JPEG","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H, et al. Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol. 2023;41(30):4794\u2013820. https:\/\/doi.org\/10.1200\/JCO.23.01136\/ASSET\/IMAGES\/LARGE\/JCO.23.01136TA2.JPEG.","journal-title":"J Clin Oncol."},{"key":"19260_CR9","unstructured":"Melanoma: cutaneous\u2014guidelines detail. Accessed 8 April 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1492"},{"issue":"4","key":"19260_CR10","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1245\/s10434-022-12866-6","volume":"30","author":"J P\u00e9rez-Morales","year":"2023","unstructured":"P\u00e9rez-Morales J, Broman KK, Bettampadi D, Haver MK, Zager JS, Schabath MB. Recurrence patterns for regionally metastatic melanoma treated in the era of adjuvant therapy: a systematic review and meta-analysis. Ann Surg Oncol. 2023;30(4):2364\u201374. https:\/\/doi.org\/10.1245\/s10434-022-12866-6.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"19260_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.22.00533","volume":"41","author":"JS Weber","year":"2023","unstructured":"Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41(3):517\u201327. https:\/\/doi.org\/10.1200\/JCO.22.00533.","journal-title":"J Clin Oncol."},{"issue":"8","key":"19260_CR12","doi-asserted-by":"publisher","first-page":"e004417","DOI":"10.1136\/JITC-2021-004417","volume":"10","author":"Z Eroglu","year":"2022","unstructured":"Eroglu Z, Broman KK, Thompson JF, et al. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection. J Immunother Cancer. 2022;10(8):e004417. https:\/\/doi.org\/10.1136\/JITC-2021-004417.","journal-title":"J Immunother Cancer."},{"issue":"13","key":"19260_CR13","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/CNCR.33483","volume":"127","author":"KK Broman","year":"2021","unstructured":"Broman KK, Hughes T, Dossett L, et al. Active surveillance of patients who have sentinel node positive melanoma: an international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021;127(13):2251\u201361. https:\/\/doi.org\/10.1002\/CNCR.33483.","journal-title":"Cancer."},{"issue":"3","key":"19260_CR14","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1245\/s10434-023-14526-9","volume":"31","author":"CA Gjorup","year":"2024","unstructured":"Gjorup CA, Woodford R, Li I, et al. Role of concurrent ultrasound surveillance of sentinel node-positive node fields in melanoma patients having routine cross-sectional imaging. Ann Surg Oncol. 2024;31(3):1857\u201364. https:\/\/doi.org\/10.1245\/s10434-023-14526-9.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"19260_CR15","doi-asserted-by":"publisher","first-page":"6978","DOI":"10.1245\/S10434-021-10570-5","volume":"28","author":"KK Broman","year":"2021","unstructured":"Broman KK, Bettampadi D, P\u00e9rez-Morales J, et al. Surveillance of sentinel node positive melanoma patients who receive adjuvant therapy without undergoing completion lymph node dissection. Ann Surg Oncol. 2021;28(12):6978. https:\/\/doi.org\/10.1245\/S10434-021-10570-5.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"19260_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(15)70122-1.","journal-title":"Lancet Oncol."},{"issue":"5","key":"19260_CR17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandal\u00e0 M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(21)00065-6.","journal-title":"Lancet Oncol."},{"issue":"19","key":"19260_CR18","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMOA1708539\/SUPPL_FILE\/NEJMOA1708539_DISCLOSURES.PDF","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u201323. https:\/\/doi.org\/10.1056\/NEJMOA1708539\/SUPPL_FILE\/NEJMOA1708539_DISCLOSURES.PDF.","journal-title":"N Engl J Med."},{"issue":"4","key":"19260_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","volume":"19","author":"M Maio","year":"2018","unstructured":"Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19(4):510\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(18)30106-2.","journal-title":"Lancet Oncol."},{"issue":"10358","key":"19260_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","volume":"400","author":"E Livingstone","year":"2022","unstructured":"Livingstone E, Zimmer L, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet. 2022;400(10358):1117\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(22)01654-3.","journal-title":"Lancet."},{"issue":"4","key":"19260_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/S00262-022-03302-5","volume":"72","author":"JS Weber","year":"2023","unstructured":"Weber JS, Poretta T, Stwalley BD, et al. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer Immunol Immunother. 2023;72(4):945\u201354. https:\/\/doi.org\/10.1007\/S00262-022-03302-5.","journal-title":"Cancer Immunol Immunother."},{"issue":"10236","key":"19260_CR22","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","volume":"395","author":"L Zimmer","year":"2020","unstructured":"Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395(10236):1558\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(20)30417-7.","journal-title":"Lancet."},{"issue":"17","key":"19260_CR23","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin J, Del Vecchio M, Mandal\u00e1 M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-Year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023;29(17):3352\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3145.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"19260_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/IJC.34462","volume":"153","author":"V De Falco","year":"2023","unstructured":"De Falco V, Suarato G, Napolitano R, et al. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: data from two Academic Italian Institutions. Int J Cancer. 2023;153(1):133\u201340. https:\/\/doi.org\/10.1002\/IJC.34462.","journal-title":"Int J Cancer."},{"issue":"9","key":"19260_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/JAMASURG.2022.2055","volume":"157","author":"JS Crystal","year":"2022","unstructured":"Crystal JS, Thompson JF, Hyngstrom J, et al. Therapeutic value of sentinel lymph node biopsy in patients with melanoma: a randomized clinical trial. JAMA Surg. 2022;157(9):835\u201342. https:\/\/doi.org\/10.1001\/JAMASURG.2022.2055.","journal-title":"JAMA Surg."},{"issue":"1","key":"19260_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2013.08.023","volume":"50","author":"APT van der Ploeg","year":"2014","unstructured":"van der Ploeg APT, van Akkooi ACJ, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer. 2014;50(1):111\u201320. https:\/\/doi.org\/10.1016\/j.ejca.2013.08.023.","journal-title":"Eur J Cancer."},{"issue":"1","key":"19260_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jamcollsurg.2005.03.029","volume":"201","author":"MS Sabel","year":"2005","unstructured":"Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201(1):37\u201347. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2005.03.029.","journal-title":"J Am Coll Surg."},{"issue":"6","key":"19260_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(16)00141-8.","journal-title":"Lancet Oncol."},{"issue":"7","key":"19260_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1310460.","journal-title":"N Engl J Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19260-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:27:30Z","timestamp":1778869650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19260"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19260-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}